Last Price
7.82
Today's Change
-2.87 (26.84%)
Day's Change
7.39 - 8.23
Trading Volume
5,233,319
Profile
AVDL
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Gregory J. Divis Jr. Mr. Gregory J. Divis Jr.
Full Time Employees: 154 154
IPO Date: 1996-06-07 1996-06-07
CIK: 0001012477 0001012477
ISIN: US05337M1045 US05337M1045
CUSIP: 05337M104 05337M104
Beta: 1.63 1.63
Last Dividend: 0.00 0.00
Dcf Diff: 7.82 7.82
Dcf: -0.12 -0.12
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Latest Videos
Apps
Top Articles
1
CEO Morning Brief
US Fed’s Waller Supports Further Cuts, Says Inflation Moving Lower
2
CEO Morning Brief
3
CEO Morning Brief
Tesla Poised for US$1 Bil Windfall From EU’s Emissions Curbs
4
CEO Morning Brief
5
CEO Morning Brief
US 30-year Mortgage Rate Just Shy of 7% Bridles Home Purchases
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
